A 3-miRNA signature for noninvasive breast cancer detection

IF 2.5 3区医学 Q2 ONCOLOGY

Seminars in oncology Pub Date : 2025-06-11 DOI:10.1016/j.seminoncol.2025.152363

Amir Ebrahimi , Davood Ghavi , Zohreh Mirzaei , Tahereh Barati , Mahmood Shekari-Khaniani , Hossein Gahramani-almangadim , Sima Mansoori-Derakhshan

{"title":"A 3-miRNA signature for noninvasive breast cancer detection","authors":"Amir Ebrahimi , Davood Ghavi , Zohreh Mirzaei , Tahereh Barati , Mahmood Shekari-Khaniani , Hossein Gahramani-almangadim , Sima Mansoori-Derakhshan","doi":"10.1016/j.seminoncol.2025.152363","DOIUrl":null,"url":null,"abstract":"<div><div>As a key component of epigenetics, microRNAs (miRNAs) have provided promising insights into several aspects of Breast Cancer (BC). We have analyzed 2 BC tissue microarray datasets (GSE26659 and GSE40525), as well as 2 serum datasets (GSE106817 and GSE113486). The results were then intersected to identify commonly dysregulated miRNAs in the tissue and serum of BC patients. RNA-seq analysis was then applied to The Cancer Genome Atlas (TCGA) data. Briefly, 79 dysregulated miRNAs were identified in the tissue and serum of patients with BC of which 3 significantly dysregulated and previously unstudied miRNAs, let-7e-5p, miR-151a-5p and miR-887-3p, were chosen for quantification in the serum of cancer patients by RT-PCR followed by evaluation of their diagnostic and prognostic features. RT-PCR analysis revealed overexpression of let-7e-5p (logFC = 2.01, <em>P</em> < .05) and miR-151a-5p (logFC = 1.48, <em>P</em> < .05) whereas miR-887-3p was downregulated (logFC = 0.62, <em>P</em> < .05) similar to microarray and RNA-seq data analysis. Based on regression analysis, a 3 miRNA-signature biomarker was proposed which had better diagnostic ability (AUC = 84.17%) compared to the ability of these miRNAs when assessed individually. Moreover, enrichment analysis revealed these miRNAs mediate vital cellular processes and biological functions that influence the development of cancer. Similarly, significant prognostic clinical characteristics were observed for these miRNAs. Overall, we have identified and validated a novel and proficient signature biomarker in serum of BC patients consisting of 3 miRNAs.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 4","pages":"Article 152363"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775425000557","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

As a key component of epigenetics, microRNAs (miRNAs) have provided promising insights into several aspects of Breast Cancer (BC). We have analyzed 2 BC tissue microarray datasets (GSE26659 and GSE40525), as well as 2 serum datasets (GSE106817 and GSE113486). The results were then intersected to identify commonly dysregulated miRNAs in the tissue and serum of BC patients. RNA-seq analysis was then applied to The Cancer Genome Atlas (TCGA) data. Briefly, 79 dysregulated miRNAs were identified in the tissue and serum of patients with BC of which 3 significantly dysregulated and previously unstudied miRNAs, let-7e-5p, miR-151a-5p and miR-887-3p, were chosen for quantification in the serum of cancer patients by RT-PCR followed by evaluation of their diagnostic and prognostic features. RT-PCR analysis revealed overexpression of let-7e-5p (logFC = 2.01, P < .05) and miR-151a-5p (logFC = 1.48, P < .05) whereas miR-887-3p was downregulated (logFC = 0.62, P < .05) similar to microarray and RNA-seq data analysis. Based on regression analysis, a 3 miRNA-signature biomarker was proposed which had better diagnostic ability (AUC = 84.17%) compared to the ability of these miRNAs when assessed individually. Moreover, enrichment analysis revealed these miRNAs mediate vital cellular processes and biological functions that influence the development of cancer. Similarly, significant prognostic clinical characteristics were observed for these miRNAs. Overall, we have identified and validated a novel and proficient signature biomarker in serum of BC patients consisting of 3 miRNAs.

查看原文本刊更多论文

无创乳腺癌检测的3-miRNA特征

作为表观遗传学的关键组成部分，microRNAs （miRNAs）为乳腺癌（BC）的几个方面提供了有希望的见解。我们分析了2个BC组织芯片数据集（GSE26659和GSE40525），以及2个血清数据集（GSE106817和GSE113486）。然后将结果交叉以鉴定BC患者组织和血清中常见的失调mirna。然后将RNA-seq分析应用于癌症基因组图谱（TCGA）数据。简而言之，我们在BC患者的组织和血清中发现了79个失调的mirna，其中3个显著失调且以前未研究的mirna， let-7e-5p， miR-151a-5p和miR-887-3p，通过RT-PCR在癌症患者的血清中进行量化，然后评估其诊断和预后特征。rt - pcr分析显示过度let-7e-5p (logFC = 2.01,P & lt; . 05)和mir - 151 - 5 - P (logFC = 1.48,P & lt; . 05)而mir - 887 - 3 - P是表达下调(logFC = 0.62,P & lt; . 05)类似于微阵列和RNA-seq数据分析。基于回归分析，提出了一个3 mirna标记生物标志物，与单独评估这些mirna相比，该标志物具有更好的诊断能力（AUC = 84.17%）。此外，富集分析显示这些mirna介导影响癌症发展的重要细胞过程和生物学功能。同样，观察到这些mirna具有显著的预后临床特征。总的来说，我们已经在BC患者的血清中鉴定并验证了一种由3个mirna组成的新型且熟练的标志性生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.